Summary of Key Information:

Reporting Period: Quarter and Half Year Ended September 30, 2026

Nature of Filing / Announcement: Outcome of Board Meeting - Unaudited Financial Results

Audit Opinion:

Limited Review Report - No modifications or qualifications. The auditors stated: "nothing has come to our attention that causes us to believe that the accompanying Statement... contains any material misstatement."

Key Financial Highlights [₹ in Lakhs]:

Consolidated Results:

Quarter Ended September 30, 2026:

  • Revenue from Operations: 74,650.19 (vs 41,157.58 in Q2 FY25 - 81% increase YoY)
  • Total Income: 75,518.71 (vs 41,621.21 in Q2 FY25)
  • Net Profit: 8,889.47 (vs 4,087.46 in Q2 FY25 - 117% increase YoY)
  • EPS: ₹1.62 (vs ₹0.75 in Q2 FY25)
  • Other Equity: 127,154.84 (vs 113,685.46 as of March 31, 2026)
  • Cash and Cash Equivalents: 15,495.77

Half Year Ended September 30, 2026:

  • Revenue from Operations: 131,663.00 (vs 83,681.46 in H1 FY25 - 57% increase YoY)
  • Total Income: 133,049.86 (vs 84,585.94 in H1 FY25)
  • Net Profit: 14,529.41 (vs 5,162.29 in H1 FY25 - 181% increase YoY)
  • EPS: ₹2.65 (vs ₹0.95 in H1 FY25)

Standalone Results:

Quarter Ended September 30, 2026:

  • Revenue from Operations: 67,799.85 (vs 36,952.63 in Q2 FY25 - 83% increase YoY)
  • Total Income: 68,643.30 (vs 37,417.92 in Q2 FY25)
  • Net Profit: 7,787.20 (vs 1,437.73 in Q2 FY25 - 441% increase YoY)
  • EPS: ₹1.42 (vs ₹0.26 in Q2 FY25)
  • Other Equity: 125,445.77 (vs 113,317.44 as of March 31, 2026)
  • Cash and Cash Equivalents: 13,980.76

Half Year Ended September 30, 2026:

  • Revenue from Operations: 121,903.98 (vs 76,081.06 in H1 FY25 - 60% increase YoY)
  • Total Income: 123,278.52 (vs 76,955.58 in H1 FY25)
  • Net Profit: 13,187.03 (vs 2,243.85 in H1 FY25 - 488% increase YoY)
  • EPS: ₹2.41 (vs ₹0.41 in H1 FY25)

Segment-wise Performance:

The company is engaged in the Pharmaceutical Business Segment.

Corporate Actions:

  • Final dividend of ₹0.20 per equity share (face value ₹2.00 each) was approved by shareholders in the AGM held on September 26, 2026, and paid on October 13, 2026.

Other Significant Information:

Consolidated Entities:

The consolidated results include:

  • Parent: Morepen Laboratories Limited
  • Indian Subsidiaries: Morepen Rx Ltd., Morepen Medipath Limited, Sigmacheck Health Private Limited, Morepen Devices Limited
  • Foreign Subsidiaries: Morepen Bio Inc., USA; Morepen Labs FZE, DAE; Morepen Medical Equipment Trading L.L.C., UAE

Consolidated Assets and Liabilities (as of September 30, 2026):

  • Total Assets: ₹230,592.47 lakhs
  • Property, Plant and Equipment: ₹42,135.47 lakhs
  • Inventories: ₹32,357.63 lakhs
  • Trade Receivables: ₹34,451.61 lakhs
  • Total Equity: ₹138,113.25 lakhs
  • Borrowings: ₹18,377.46 lakhs (current) + ₹12,119.34 lakhs (non-current)
  • Trade Payables: ₹40,804.00 lakhs (₹207.75 lakhs to MSME, ₹40,596.25 lakhs to others)

Standalone Assets and Liabilities (as of September 30, 2026):

  • Total Assets: ₹224,708.33 lakhs
  • Property, Plant and Equipment: ₹33,651.96 lakhs
  • Inventories: ₹21,341.92 lakhs
  • Trade Receivables: ₹32,902.15 lakhs
  • Total Equity: ₹136,404.18 lakhs
  • Borrowings: ₹18,338.00 lakhs (current) + ₹12,065.31 lakhs (non-current)
  • Trade Payables: ₹31,212.57 lakhs (₹128.38 lakhs to MSME, ₹31,084.19 lakhs to others)